Take the guesswork out of HF care

  • Provides total blood and red blood cell volume along with calculated patient-specific ideals*
  • Actionable results—quantifies the excess or deficit with 98% accuracy
  • Confidently identify and address anemia, regardless of plasma expansion or depletion
  • Non-invasive, single-venipuncture technique
  • Over 40,000 tests performed in over 75 hospitals
  • Fully reimbursed by Medicare

Lower real-world heart failure mortality and readmissions with individualized care guided by direct blood volume analysis (BVA)

In a large mixed heart failure (HF) community cohort (n=250), individualized management guided by BVA significanlty improved key outcomes vs Medicare benchmarks1


Retrospective analysis of n=250 patients treated in an East Coast community hospital HF practice, 2008-2012, who underwent BVA at least once and for whom at least 1 year of follow-up data were available or death was recorded within 1 year. Cohort outcomes, which were not risk-adjusted, were analyzed vs institutional (30-day) or national (365-day) Medicare benchmarks.2 Decongestion and anemia management strategies were per best clinical judgment integrating BVA results alongside other data. Patients were 41% female and 59% male; age range was 42 to 95 years; 46% had reduced and 54% preserved ejection fraction, with an ejection fraction range of 10%-80%; 30% had Stage 4 and 58% Stage 2 or 3 chronic kidney disease.

Volume and red blood cell status heterogeneity was high, suggesting a medical need for the direct, accurate evaluation only possible with BVA.

  • The high heterogeneity observed in this cohort is consistent with previously published observational data in HF for total blood volume3-5 and red blood cell volume3,5-7 status

BVA touchpoints

Points of contact in HF care at which to consider direct BVA


The extent, composition and distribution of volume overload in decompensated heart failure are highly variable, and this variability needs to be taken into account in the approach to individualized therapy.“3

- Wayne L.Miller, M.D.

  • *Derived from Metropolitan Life height, weight, and gender data in a uniquely accurate, validated methodology.8,9
    †A131| labeled albumin tracer injection (>25 microcuries: no requirement for thyroid blockade10) is followed by 5 blood draws 5-6 minutes apart. The Daxor BVA-100 measures plasma dilution in successive samples and performs a regression analysis to arrive at the total blood volume. Institutional procedural variance drives a real-world time range of ~45-90 minutes for full results; preliminary results may be obtained in < 30 minutes.

References: 1. Strobeck JE, et al. Impact of blood volume quantification on decongestion strategy, readmission rates (RR), and mortality in hospitalized heart failure patients (HHF). Poster presented at American College of Cardiology 6th Annual Scientific Session; April 2016; Chicago, IL; abstract 1160M-01. 2. Centers for Medicare & Medicaid Services: Readmissions and Deaths. Retrieved from https://data.medicare.gov, December 29, 2015. 3. Miller WL, et al. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management. J Am Coll Cardiol HF 2014;2:298-305. 4. Androne AS, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 2004;93:1254-1259. 5. Miller WL, et al. Volume overload profiles in patients with preserved and reduced ejection fraction chronic heart failure: is there a difference? J Am Coll Cardiol HF 2016;4:453-459. 6. Miller WL, et al. Peripheral venous hemoglobin and red blood cell mass mismatch in volume overload systolic heart failure: implications for patient management. J Cardiovasc Trans Res 2015;8:404-410. 7. Androne AS, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-229. 8. Feldschuh J, et al. Prediction of the normal blood volume—relation of blood volume to body habitus. Circulation 1977;56(4):605- 612. 9. Feldschuh J, et al. The importance of correct norms in blood volume measurement. Am J Med Sci 2007;334(1):41-46. 10. Volumex [package insert]. Daxor Corporation, New York, NY; 2005.